Trenchant BioSystems and engineering partner Invetech announced a collaboration to finalize and commercialize the AutoCell platform, a fully automated cell‑and‑gene therapy (CGT) manufacturing solution intended for point‑of‑care deployment. Internal and independent data released by Trenchant suggest AutoCell can reduce or eliminate ex vivo expansion steps and source T cells from a single unit of whole blood. The partners aim for an early access launch in 2027 and full commercial release later that year. Both firms framed the deal as a step toward distributed manufacturing that could lower cost‑of‑goods and expand patient access for autologous and other CGT products.